Then, TrxFTL was further evaluated in a panel of distinct human cancer cell lines of colon (HCT116 p53+/+ and HCT116 p53−/−), melanoma (A375), triple-negative breast cancer (MDA-MB-231), and ovarian (IGROV-1), using the SRB assay. Here, TP53 is linked to triple-negative breast carcinoma.